Outcomes and short-term follow-up for the overall cohort and by myocardial injury.
| . | Overall (n = 367) . | Without myocardial injury (n = 198) . | Myocardial injury(n = 169) . | P value . |
|---|---|---|---|---|
| In-hospital outcomes | ||||
| Length of stay (days) – median (IQR) | 7 | 5 | 9 | <0.0001 |
| ARDS—n (%) | 66 (18) | 22 (11) | 44 (26) | 0.0002 |
| Cardiac arrest—n (%) | 12 (3.3) | 5 (2.5) | 7 (4.1) | 0.39 |
| Coagulopathy—n (%) | 8 (2.2) | 3 (1.5) | 5 (3) | 0.35 |
| Shock—n (%) | 46 (13) | 10 (5.1) | 36 (21) | <0.0001 |
| Respiratory failure requiring mechanical ventilation—n (%) | 59 (16) | 17 (8.6) | 42 (25) | <0.0001 |
| Pulmonary embolism—n (%) | 14 (3.8) | 4 (2) | 10 (5.9) | 0.0521 |
| ICU admission—n (%) | 102 (28) | 36 (18) | 66 (39) | <0.0001 |
| Clinical heart failure—n(%) | 24 (6.5) | 3 (1.5) | 21 (12) | <0.0001 |
| Co-infection—n (%) | 79 (22) | 27 (14) | 52 (31) | <0.0001 |
| In-hospital death—n (%) | 32 (8.7) | 7 (3.5) | 25 (15) | <0.0001 |
| Postdischarge short-term outcomes among survivals | ||||
| COVID-19 related hospitalization—n (%) | 30(9.6) | 14 (8) | 16(12) | 0.28 |
| Acute MI—n (%) | 0 (0) | 0 (0) | 0 (0) | NA |
| Death within 30-days postdischarge—n (%) | 11(3.5) | 2 (1.1) | 9(6.6) | 0.01 |
| . | Overall (n = 367) . | Without myocardial injury (n = 198) . | Myocardial injury(n = 169) . | P value . |
|---|---|---|---|---|
| In-hospital outcomes | ||||
| Length of stay (days) – median (IQR) | 7 | 5 | 9 | <0.0001 |
| ARDS—n (%) | 66 (18) | 22 (11) | 44 (26) | 0.0002 |
| Cardiac arrest—n (%) | 12 (3.3) | 5 (2.5) | 7 (4.1) | 0.39 |
| Coagulopathy—n (%) | 8 (2.2) | 3 (1.5) | 5 (3) | 0.35 |
| Shock—n (%) | 46 (13) | 10 (5.1) | 36 (21) | <0.0001 |
| Respiratory failure requiring mechanical ventilation—n (%) | 59 (16) | 17 (8.6) | 42 (25) | <0.0001 |
| Pulmonary embolism—n (%) | 14 (3.8) | 4 (2) | 10 (5.9) | 0.0521 |
| ICU admission—n (%) | 102 (28) | 36 (18) | 66 (39) | <0.0001 |
| Clinical heart failure—n(%) | 24 (6.5) | 3 (1.5) | 21 (12) | <0.0001 |
| Co-infection—n (%) | 79 (22) | 27 (14) | 52 (31) | <0.0001 |
| In-hospital death—n (%) | 32 (8.7) | 7 (3.5) | 25 (15) | <0.0001 |
| Postdischarge short-term outcomes among survivals | ||||
| COVID-19 related hospitalization—n (%) | 30(9.6) | 14 (8) | 16(12) | 0.28 |
| Acute MI—n (%) | 0 (0) | 0 (0) | 0 (0) | NA |
| Death within 30-days postdischarge—n (%) | 11(3.5) | 2 (1.1) | 9(6.6) | 0.01 |
ARDS, acute respiratory distress symptoms. ICU: intensive care unit. COVID-19: coronavirus disease 2019. MI: myocardial infarction.
Outcomes and short-term follow-up for the overall cohort and by myocardial injury.
| . | Overall (n = 367) . | Without myocardial injury (n = 198) . | Myocardial injury(n = 169) . | P value . |
|---|---|---|---|---|
| In-hospital outcomes | ||||
| Length of stay (days) – median (IQR) | 7 | 5 | 9 | <0.0001 |
| ARDS—n (%) | 66 (18) | 22 (11) | 44 (26) | 0.0002 |
| Cardiac arrest—n (%) | 12 (3.3) | 5 (2.5) | 7 (4.1) | 0.39 |
| Coagulopathy—n (%) | 8 (2.2) | 3 (1.5) | 5 (3) | 0.35 |
| Shock—n (%) | 46 (13) | 10 (5.1) | 36 (21) | <0.0001 |
| Respiratory failure requiring mechanical ventilation—n (%) | 59 (16) | 17 (8.6) | 42 (25) | <0.0001 |
| Pulmonary embolism—n (%) | 14 (3.8) | 4 (2) | 10 (5.9) | 0.0521 |
| ICU admission—n (%) | 102 (28) | 36 (18) | 66 (39) | <0.0001 |
| Clinical heart failure—n(%) | 24 (6.5) | 3 (1.5) | 21 (12) | <0.0001 |
| Co-infection—n (%) | 79 (22) | 27 (14) | 52 (31) | <0.0001 |
| In-hospital death—n (%) | 32 (8.7) | 7 (3.5) | 25 (15) | <0.0001 |
| Postdischarge short-term outcomes among survivals | ||||
| COVID-19 related hospitalization—n (%) | 30(9.6) | 14 (8) | 16(12) | 0.28 |
| Acute MI—n (%) | 0 (0) | 0 (0) | 0 (0) | NA |
| Death within 30-days postdischarge—n (%) | 11(3.5) | 2 (1.1) | 9(6.6) | 0.01 |
| . | Overall (n = 367) . | Without myocardial injury (n = 198) . | Myocardial injury(n = 169) . | P value . |
|---|---|---|---|---|
| In-hospital outcomes | ||||
| Length of stay (days) – median (IQR) | 7 | 5 | 9 | <0.0001 |
| ARDS—n (%) | 66 (18) | 22 (11) | 44 (26) | 0.0002 |
| Cardiac arrest—n (%) | 12 (3.3) | 5 (2.5) | 7 (4.1) | 0.39 |
| Coagulopathy—n (%) | 8 (2.2) | 3 (1.5) | 5 (3) | 0.35 |
| Shock—n (%) | 46 (13) | 10 (5.1) | 36 (21) | <0.0001 |
| Respiratory failure requiring mechanical ventilation—n (%) | 59 (16) | 17 (8.6) | 42 (25) | <0.0001 |
| Pulmonary embolism—n (%) | 14 (3.8) | 4 (2) | 10 (5.9) | 0.0521 |
| ICU admission—n (%) | 102 (28) | 36 (18) | 66 (39) | <0.0001 |
| Clinical heart failure—n(%) | 24 (6.5) | 3 (1.5) | 21 (12) | <0.0001 |
| Co-infection—n (%) | 79 (22) | 27 (14) | 52 (31) | <0.0001 |
| In-hospital death—n (%) | 32 (8.7) | 7 (3.5) | 25 (15) | <0.0001 |
| Postdischarge short-term outcomes among survivals | ||||
| COVID-19 related hospitalization—n (%) | 30(9.6) | 14 (8) | 16(12) | 0.28 |
| Acute MI—n (%) | 0 (0) | 0 (0) | 0 (0) | NA |
| Death within 30-days postdischarge—n (%) | 11(3.5) | 2 (1.1) | 9(6.6) | 0.01 |
ARDS, acute respiratory distress symptoms. ICU: intensive care unit. COVID-19: coronavirus disease 2019. MI: myocardial infarction.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
